Опыт лечения первично-рефрактерной лимфомы Ходжкина (клинический случай)

Гущина Е.Е., Вернюк М.А., Червонцева А.М., Черкашина И.В., Хайруллина Л.С., Лунин В.В., Феденко А.А. Опыт лечения первично-рефрактерной лимфомы Ходжкина (клинический случай). Современная Онкология. 2022;24(2):254–258. DOI: 10.26442/18151434.2022.2.201518

________________________________________________

Gushchina EE, Vernyuk MA, Chervontseva AM, Cherkashina IV, Khairullina LS, Lunin VV, Fedenko AA. Own experience in the treatment of primary refractory Hodgkin's lymphoma. Case report. Journal of Modern Oncology. 2022;24(2):254–258. DOI: 10.26442/18151434.2022.2.201518

Читать PDF

Аннотация

Несмотря на значительные успехи, достигнутые в последние десятилетия в терапии классической лимфомы Ходжкина, у 10–30% пациентов отмечается рефрактерное течение или рецидив заболевания. Эффективность терапии 2-й и последующих линий составляет около 50%. Настоящим прорывом в лечении рецидивирующих/рефрактерных форм классической лимфомы Ходжкина стало появление таргетных препаратов. Включение новых препаратов в стандартные режимы терапии спасения значительно улучшает их эффективность. Представлен клинический опыт лечения пациента с прогрессированием классической лимфомы Ходжкина после терапии первой линии, применением брентуксимаб ведотина в комбинации с бендамустином в качестве терапии спасения с достижением полной ремиссии, последующим выполнением высокодозной консолидации с трансплантацией аутологичных гемопоэтических стволовых клеток.

Ключевые слова: рецидивирующая/рефрактерная лимфома Ходжкина, брентуксимаб ведотин, терапия спасения

________________________________________________

Despite significant progress made in recent decades in the treatment of classical Hodgkin's lymphoma, in 10–30% of patients develop a refractory course or relapse of the disease. The effectiveness of therapy of the second and subsequent lines is about 50%. A significant breakthrough in the treatment of recurrent/refractory forms of classical Hodgkin's lymphoma has been the introduction of targeted drugs. The inclusion of new drugs in previously standard rescue therapy regimens significantly improves the effectiveness of the therapy. A clinical case of treating a patient with the progression of classical Hodgkin's lymphoma after first-line therapy, the use of brentuximab vedotin in combination with bendamustine as a rescue therapy with the achievement of complete remission, followed by high-dose consolidation with autologous hematopoietic stem cell transplantation is presented.

Keywords: relapsed/refractory Hodgkin lymphoma, brentuximab vedotin, salvage therapy

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398(10310):1518-27. DOI:10.1016/S0140-6736(20)32207-8
2. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-9. DOI:10.1182/blood-2005-06-2252
3. Mauch PM, Armitage JO, Diehl V, et al. Hodgkin’s Disease. Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
4. Castagna L, Santoro A, Carlo-Stella C. Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes. J Blood Med. 2020;11:389-403. DOI:10.2147/JBM.S250581
5. Josting A, Müller H, Borchmann P, et al. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin’s Lymphoma. J Clin Oncol. 2010;28(34):5074-80. DOI:10.1200/JCO.2010.30.5771
6. Radford J, Illidge T, Counsell N, et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. N Engl J Med. 2015;372(17):1598-607. DOI:10.1056/NEJMoa1408648
7. André MPE, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response – Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786-94. DOI:10.1200/JCO.2016.68.6394
8. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s Lymphoma When High-Dose Salvage Is Planned. N Engl J Med. 2011;365(3):203‑12. DOI:10.1056/NEJMoa1100340
9. Yung L, Linch D. Hodgkin’s lymphoma. Lancet. 2003;361(9361):943-51. DOI:10.1016/S0140-6736(03)12777-8
10. Mina A, Vakkalagadda C, Pro B. Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy. Cancers (Basel). 2019;11(3):421. DOI:10.3390/cancers11030421
11. Shotton R, Kirkwood AA, Northend M, et al. Real world outcomes and responses to second-line therapy in relapsed/refractory Hodgkin lymphoma: a multicentre UK study. Hematol Oncol. 2021;39(S2). DOI:10.1002/hon.106_2880
12. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16(1):116-23. DOI:10.1093/annonc/mdi003
13. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-23. DOI:10.1182/blood.V97.3.616
14. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-9. DOI:10.1093/annonc/mdm090
15. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35-41. DOI:10.3324/haematol.10661
16. Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation. Cancer. 2006;106(2):353-60. DOI:10.1002/cncr.21587
17. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665-70. DOI:10.1182/blood-2011-10-388058
18. Labrador J, Cabrero-Calvo M, Pérez-López E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol. 2014;93(10):1745‑53. DOI:10.1007/s00277-014-2114-0
19. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762-7. DOI:10.1093/annonc/mdg496
20. Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-40. DOI:10.1182/bloodadvances.2019000984
21. Sureda A, André M, Borchmann P, et al. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer. 2020;20(1):1088. DOI:10.1186/s12885-020-07561-2
22. Chen R, Palmer JM, Martin P, et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-40. DOI:10.1016/j.bbmt.2015.07.018
23. Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-92.
DOI:10.1016/S1470-2045(15)70013-6
24. LaCasce AS, Bociek RG, Sawas A, et al. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2020;189(3). DOI:10.1111/bjh.16499
25. Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30(4):612‑20. DOI:10.1093/annonc/mdz009
26. Abuelgasim KA, Alzahrani M, Alsharhan Y, et al. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2019;54(7):1168-72. DOI:10.1038/s41409-019-0454-z
27. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-39. DOI:10.1200/JCO.2017.76.0793
28. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-94. DOI:10.1182/blood-2017-10-811224
29. Chen R, Zinzani PL, Fanale MA, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125-32. DOI:10.1200/JCO.2016.72.1316
30. Moskowitz AJ, Shah G, Schöder H, et al. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021;39(28):3109-17. DOI:10.1200/JCO.21.01056
31. Johnston PB, Pinter-Brown LC, Warsi G, et al. Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Exp Hematol Oncol. 2018;7(1):12. DOI:10.1186/s40164-018-0103-z
32. Oki Y, Buglio D, Fanale M, et al. Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. Clin Cancer Res. 2013;19(24):6882-90. DOI:10.1158/1078-0432.CCR-13-1906
33. Phillips TJ, Forero-Torres A, Sher T, et al. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood. 2018;132(3):293-306. DOI:10.1182/blood-2017-10-812701
34. Baryakh EA. Treatment of relapse and refractory Hodgkin lymphoma. Oncohematology. 2017;12(2):8-13. DOI:10.17650/1818-8346-2017-12-2-8-13
35. Chervontseva AM, Verniuk MA, Gushchina EE, et al. Experience in the treatment of refractory hodgkin’s lymphoma. Sib J Oncol. 2021;20(1):155-61.
DOI:10.21294/1814-4861-2021-20-1-155-161

________________________________________________

Авторы

Е.Е. Гущина*, М.А. Вернюк, А.М. Червонцева, И.В. Черкашина, Л.С. Хайруллина, В.В. Лунин, А.А. Феденко

Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия

________________________________________________

Elizaveta E. Gushchina*, Maria A. Vernyuk, Alevtina M. Chervontseva, Irina V. Cherkashina, Liliya S. Khayrullina, Vladimir V. Lunin, Alexander A. Fedenko

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre, Moscow, Russia

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.